Legal & General Group’s Immunome IMNM Stock Holding History

Legal & General Group’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	89,623 +8,035	+10%	+$172K	﹤0.01%	1986
2026 Q1	$1.78M	Sell	81,588 -13,370	-14%	-$298K	﹤0.01%	1957
2025 Q4	$2.04M	Buy	94,958 +13,885	+17%	+$244K	﹤0.01%	1958
2025 Q3	$949K	Buy	81,073 +18,044	+29%	+$179K	﹤0.01%	2255
2025 Q2	$586K	Buy	63,029 +526	+0.8%	+$4.31K	﹤0.01%	2399
2025 Q1	$421K	Buy	62,503 +20,510	+49%	+$197K	﹤0.01%	2448
2024 Q4	$446K	Sell	41,993 -90	-0.2%	-$1.09K	﹤0.01%	2496
2024 Q3	$615K	Buy	42,083 +222	+0.5%	+$3.15K	﹤0.01%	2393
2024 Q2	$507K	Buy	41,861 +11,133	+36%	+$174K	﹤0.01%	2417
2024 Q1	$758K	Buy	+30,728	New	+$624K	﹤0.01%	2282
2021 Q2	–	Sell	-207	Closed	-$7K	–	3574
2021 Q1	$7K	Buy	+207	New	+$5.14K	﹤0.01%	3448

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Legal & General Group's IMNM Position: Q2 2026 in Review

Legal & General Group increased its Immunome (IMNM) stake by 9.8% in Q2 2026, buying an estimated $172K and bringing the position to 89,623 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1986.

Legal & General Group first reported a position in IMNM in Q1 2021 and has held it in 11 quarters since. The position peaked at $2.04M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

Legal & General Group held 89,623 shares of Immunome worth $1.9M as of Q2 2026.
Legal & General Group bought 8,035 Immunome shares in Q2 2026, an estimated $172K.
Immunome made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1986 holding.
Legal & General Group first reported a position in Immunome in Q1 2021 and has held it in 11 quarters since.
Legal & General Group's Immunome position peaked at $2.04M in Q4 2025.
202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.